(9CI)-4-(苯基甲基)-嘧啶 | 64660-82-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: (9CI)-4-(苯基甲基)-嘧啶
• 英文名称: 4-benzylpyrimidine
• CAS: 64660-82-8
• 化学式: C₁₁H₁₀N₂
• mdl: MFCD18449350
• 分子量: 170.214
• InChiKey: BXACYQRHBZMYQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  (9CI)-4-(苯基甲基)-嘧啶 在 间氯过氧苯甲酸 作用下， 以 苯 为溶剂， 反应 18.0h， 生成 pyrimido-[1,6-a]indole
  参考文献：
  名称：

  Application of Flash Vacuum Pyrolysis to the Synthesis of 1,2-Condensed Indoles

  摘要：

  DOI：

  10.1055/s-1983-30619
• 作为产物：
  描述：

  苄基-三丁基磷鎓氯化物 在 palladium on activated charcoal magnesium oxide 作用下， 以 乙醇 、 水 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 生成 (9CI)-4-(苯基甲基)-嘧啶
  参考文献：
  名称：

  Abbotto, Alessandro; Alanzo, Vito; Bradamante, Silvia, Journal of the Chemical Society. Perkin transactions II, 1991, # 4, p. 481 - 488

  摘要：

  DOI：

文献信息

• 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY
  申请人：Greff Zoltán

  公开号：US20120258968A1

  公开（公告）日：2012-10-11

  The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R 1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula —NH—SO 2 —R 2 or heteroaryl group or NHR 3 group where R 3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

  本发明涉及通式（I）的化合物及其药用盐和溶剂化物，其中R1为卤素，乙烯基芳基，取代芳基，杂芳基或苯并[1,3]二噁唑基团，W为式—NH—SO2—R2或杂芳基或NHR3基团，其中R3为氢或杂芳基；n为1、2、3或4。此外，本发明还涉及含有至少一种通式（I）的化合物和/或其药用盐或溶剂化物的药物组合物，以及将它们用于制备用于预防和/或治疗蛋白激酶相关疾病，特别是CDK9相关疾病（例如细胞增殖性疾病、传染病、疼痛、心血管疾病和炎症）的药物组合物。
• Suzuki-Miyaura and Negishi Approaches to a Series of Forensically Relevant Pyridines and Pyrimidines
  作者：Zbigniew Czarnocki、Dariusz Błachut、Joanna Szawkało

  DOI：10.1055/s-0030-1260224

  日期：2011.11

  ridines were prepared. The synthesis of 5-aryl-4-methylpyrimidines was accomplished by Suzuki­-Miyaura cross-coupling reaction between arylboronic acids and 5-bromo-4-methylpyrimidine. The 4-benzylpyrimidines and 2,6-benzylpyridines were synthesized by treatment of 4-bromopyrimidine and 2,6-dibromopyridine derivatives with ring-substituted benzylzinc reagents. cross-coupling reaction - amphetamine

  制备了5-芳基-4-甲基嘧啶，4-苄基嘧啶，2，6-苄基吡啶和2，6-二苄基-4-甲基吡啶的苯环取代的衍生物的文库。5-芳基-4-甲基嘧啶的合成是通过芳基硼酸与5-溴-4-甲基嘧啶之间的Suzuki-Miyaura交叉偶联反应完成的。通过用环取代的苄基锌试剂处理4-溴嘧啶和2,6-二溴吡啶衍生物来合成4-苄基嘧啶和2,6-苄基吡啶。 交叉偶联反应-苯丙胺类似物-Leuckart合成-药物-杂环
• Novel heterocyclic antibacterial compounds
  申请人：——

  公开号：US20030181719A1

  公开（公告）日：2003-09-25

  The invention provides heterocyclic organic compounds that inhibit bacterial DNA polymerase IIIC and type II bacterial topoisomerase. The invention further provides compounds that are useful as intermediates in the synthesis of such heterocyclic organic compounds. Syntheses and uses of such heterocyclic organic molecules are also described.

  该发明提供了抑制细菌DNA聚合酶IIIC和类型II细菌拓扑异构酶的杂环有机化合物。该发明还提供了在合成这种杂环有机化合物中作为中间体有用的化合物。该发明还描述了这种杂环有机分子的合成和用途。
• Polymeric Reagents Comprising a Terminal Vinylic Group and Conjugates Formed Therefrom
  申请人：Culbertson Sean M.

  公开号：US20100048707A1

  公开（公告）日：2010-02-25

  The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.

  本发明提供了具有可降解连接的共轭物和用于制备这种共轭物的高分子试剂。还提供了制备高分子试剂和共轭物的方法，以及用于给予共轭物和组成物的方法。
• [EN] beta -L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B<br/>[FR] beta -L-2'-DESOXY-NUCLEOSIDES POUR LE TRAITEMENT DE L'HEPATITE B
  申请人：NORIVIO PHARMACEUTICALS LTD

  公开号：WO2000009531A2

  公开（公告）日：2000-02-24

  This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2'-deoxy-β-L-erythro-pentofuranonucleoside has formula (I) wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2'-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2'-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

  本发明涉及一种治疗乙型肝炎感染宿主的方法，包括给予有效量的抗HBV生物活性2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药，其中2'-脱氧-β-L-erythro-戊糖核苷具有式(I)，其中R选自H、直链、支链或环烷基、CO-烷基、CO-芳基、CO-烷氧基烷基、CO-芳氧基烷基、CO-取代芳基、烷基磺酰基、芳基磺酰基、芳基烷基磺酰基、氨基酸残基、单磷酸、二磷酸或三磷酸或磷酸衍生物；而基团是一种可以选择性地被取代的嘌呤或嘧啶碱基。2'-脱氧-β-L-erythro-戊糖核苷或其药学上可接受的盐或前药可以单独给予或与另一种2'-脱氧-β-L-erythro-戊糖核苷或另一种抗乙型肝炎药物联合给予。